AbbVie submitted a New Drug Application to the U.S. Food and Drug Administration for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.
Pfizer Inc. said on May 10 the company will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co., making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.
Eisai, Biogen take another step toward potential approval of Alzheimer’s drug
Alzheimer's, Alzheimer's Disease, Alzheimer's Diseases, Alzheimer’s, Alzheimer’s Disease, Alzheimer’s disease, Alzheimer’s disease, Amyloid Beta, Biogen, Biologics License Application (BLA), CNS Disorders, Dementia, Eisai, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuroscience, Priority Review, R&DEisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.
Vounatsos out as Biogen appears to concede defeat over Aduhelm
Alzheimer's Disease, Alzheimer's Diseases, Alzheimer’s, Alzheimer’s disease, Business, Centers for Medicare & Medicaid Services, Centers for Medicare and Medicaid Services (CMS), Cerebral edema, Dementia, Departures, Edema, Medicare and Medicaid Services, Medicare and Medicaid Services (CMS), Medicare Part D, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuroscience, People on the MoveBruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.
Parkinson’s Foundation Announces Major Expansion of PD GENEration Study, Increasing Access to Genetic Testing and Counseling Across the U.S.
CNS Disorders, Gene Testing, Genetic Testing, Genomic Tests, Neurodegenerative Disorders, Parkinson's, Parkinson's Disease, Parkinson's Disease, Parkinson's Disease, Parkinson’s disease, Parkinson’s disease, Parkinson’s disease, Parkinson’s Disease, Personalization, Personalized Care, Personalized health, Personalized Medicine, Personalized TherapeuticsThe Parkinson’s Foundation has announced the expansion of PD GENEration: Mapping the Future of Parkinson’s Disease, a first-of-its-kind national initiative offering genetic testing and counseling for people with Parkinson’s disease (PD) at no cost.
AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
Cassava Sciences hits back at NYT for alleged “pre-set narrative”
Alzheimer's Diseases, Alzheimer’s, Alzheimer’s Disease, Alzheimer’s disease, Alzheimer’s disease, Brain Diseases, Centers for Medicare & Medicaid Services, CNS Disorders, Dementia, Early Alzheimer's Disease, Early Alzheimer’s, Financing, Neurodegenerative Disorders, Neuroscience, New York Times, Newspapers, Papers, R&D, R&D, Research Papers, Scientific Papers, Series ACassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
Axsome Therapeutics said on April 25 the company expects the U.S. health regulator to decline approval for the drug developer’s treatment of acute migraine over unresolved issues of its quality control processes, sending shares of Axsome down 20 percent.
Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis
Acute Migraine, Episodic Migraine, Hydrocodone, Migraine, Migraine Headaches, Opioid Dependence, Opioid Prescriptions, Opioid Safety, Prescriptions, R&D, Real world evidence, Research & Development, TherapeuticsLongitudinal medical and prescription claims were used to assess opioid prescriptions and MME’s dispensed amongst migraine patients nine months prior to and nine months following Nurtec® ODT initiation. Among […]
Shares of Cassava Sciences were up more than 5% in premarket trading on February 11 after the U.S. Food and Drug Administration denied a Citizen Petition filed during 2021 on behalf of short-selling clients who sought to suspend the company’s Alzheimer’s clinical trials.